Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness ...